ACADIA Pharmaceuticals Inc. (ACAD)
- Previous Close
17.07 - Open
16.98 - Bid 16.81 x 200
- Ask 16.84 x 200
- Day's Range
16.62 - 17.30 - 52 Week Range
16.60 - 33.99 - Volume
2,781,966 - Avg. Volume
1,778,487 - Market Cap (intraday)
2.771B - Beta (5Y Monthly) 0.39
- PE Ratio (TTM)
-- - EPS (TTM)
-0.37 - Earnings Date May 6, 2024 - May 10, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
29.40
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
www.acadia.comRecent News: ACAD
Performance Overview: ACAD
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ACAD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ACAD
Valuation Measures
Market Cap
2.81B
Enterprise Value
2.43B
Trailing P/E
--
Forward P/E
26.25
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.85
Price/Book (mrq)
6.51
Enterprise Value/Revenue
3.35
Enterprise Value/EBITDA
-35.84
Financial Highlights
Profitability and Income Statement
Profit Margin
-8.44%
Return on Assets (ttm)
-6.86%
Return on Equity (ttm)
-14.73%
Revenue (ttm)
726.44M
Net Income Avi to Common (ttm)
-61.29M
Diluted EPS (ttm)
-0.37
Balance Sheet and Cash Flow
Total Cash (mrq)
438.86M
Total Debt/Equity (mrq)
13.25%
Levered Free Cash Flow (ttm)
28.44M
Research Analysis: ACAD
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell